DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Funding Opportunities
  3. Synopsis of Open Program Funding Opportunities

Funding Opportunities

Synopsis of Open Program Funding Opportunities

To view past Program Funding Opportunities, please visit the Program Funding Opportunities Archives



FY24 Breast Cancer Research Program (BCRP)

Mechanism Program Announcement/Instructions Release Date Funding Amount Submission Deadline
Breakthrough Award Levels 1 and 2 (BTA12) Program Announcement
Application Instructions		 March 25, 2024 Funding Level 1:
  • The maximum allowable funding for the entire period of performance is $450,000 for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 3 years.

Funding Level 1 with Partnering PI Option:

  • The maximum allowable funding for the entire period of performance is $750,000 for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 3 years.

Funding Level 2:

  • The maximum allowable funding for the entire period of performance is $1 million (M) for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 3 years.

Funding Level 2 – Population Science and Prevention Studies:

  • The maximum allowable funding for the entire period of performance is $1.5M for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 4 years.

Funding Level 2 with Partnering PI Option:

  • The maximum allowable funding for the entire period of performance is $1.5M for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 3 years.

Funding Level 2 – Population Science and Prevention Studies with Partnering PI Option:

  • The maximum allowable funding for the entire period of performance is $2M for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 4 years.
 Pre-Application
(Letter of Intent):
May 16, 2024
5:00 p.m. Eastern Time

Application:
May 30, 2024
11:59 p.m. Eastern Time
Breakthrough Award Level 3 (BTA3) Program Announcement
Application Instructions		 March 25, 2024 Funding Level 3:
  • Maximum funding of $4M in direct costs (plus indirect costs).
  • The maximum period of performance is 4 years.

Funding Level 3 with Partnering PI Option:

  • Maximum funding of $5M for direct costs (plus indirect costs).
  • The maximum period of performance is 4 years.
 Pre-Application
(Preproposal):
May 14, 2024
5:00 p.m. Eastern Time

Invitation to Submit an Application:
June 14, 2024
Application:
August 6, 2024
11:59 p.m. Eastern Time
Breakthrough Award Level 4 (BTA4) Program Announcement
Application Instructions		 March 25, 2024 Funding Level 4 and Funding Level 4 with Partnering PI Option:
  • The maximum allowable funding for the entire period of performance is $15M for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 4 years.
 Pre-Application
(Preproposal):
May 14, 2024
5:00 p.m. Eastern Time

Invitation to Submit an Application:
June 14, 2024
Application:
August 6, 2024
11:59 p.m. Eastern Time
Clinical Research Extension Award (CREA) Program Announcement
Application Instructions		 March 25, 2024 Clinical Research Extension Award:
  • The maximum allowable funding for the entire period of performance is $5M for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 4 years.
Clinical Research Extension Award with Partnering PI Option:
  • The maximum allowable funding for the entire period of performance is $6M for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 4 years.
 Pre-Application
(Letter of Intent):
May 23, 2024
5:00 p.m. Eastern Time

Application:
June 4, 2024
11:59 p.m. Eastern Time
Era of Hope Scholar Award (EOHS) Program Announcement
Application Instructions		 March 25, 2024
  • The maximum allowable funding for the entire period of performance is $3M for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 4 years.
 Pre-Application
(Letter of Intent):
May 23, 2024
5:00 p.m. Eastern Time

Application:
June 4, 2024
11:59 p.m. Eastern Time

Confidential Letters of Recommendation Submission Deadline:
June 7, 2024
5:00 p.m. Eastern Time
Transformative Breast Cancer Consortium Award (TBCCA) Program Announcement
Application Instructions		 March 25, 2024
  • The maximum allowable funding for the entire period of performance is $25M for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 4 years.
 Pre-Application
(Preproposal):
May 14, 2024
5:00 p.m. Eastern Time

Invitation to Submit an Application:
June 14, 2024
Application:
August 6, 2024
11:59 p.m. Eastern Time
Transformative Breast Cancer Consortium Development Award (TBCCDA) Program Announcement
Application Instructions		 May 2, 2023
  • The maximum allowable funding for the entire period of performance is $100,000 for direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
  • The maximum period of performance is 1 year.
 Pre-Application
(Letter of Intent):
May 16, 2024
5:00 p.m. Eastern Time

Application:
May 30, 2024
11:59 p.m. Eastern Time

CDMRP

Privacy Notice · External Links/Product Disclaimers · Research Programs · Funding Opportunities · Consumer Involvement · Search Awards · About Us

CDMRP © 2023

location icon

1077 Patchel Street Fort Detrick, MD 21702-5024

telephone icon

(301) 619-7071

About Us The CDMRP originated in 1992 via a Congressional appropriation to foster novel approaches to biomedical research in response to the expressed needs of its stakeholders-the American public, the military, and Congress.

- MRDC Family -

CDMRP | TATRC | USAARL | USAISR | USAMMDA | USAMRAA | USAMRICD | USAMRIID | USARIEM | WRAIR